Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Axonics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $627.1 Mil. Axonics's Total Assets for the quarter that ended in Mar. 2024 was $715.6 Mil.
Therefore, Axonics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.88.
The historical rank and industry rank for Axonics's Equity-to-Asset or its related term are showing as below:
AXNX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.55 Med: 0.85 Max: 0.93
Current: 0.88
During the past 8 years, the highest Equity to Asset Ratio of Axonics was 0.93. The lowest was -4.55. And the median was 0.85.
AXNX's Equity-to-Asset is ranked better than 87.47% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs AXNX: 0.88
Axonics Equity-to-Asset Historical Data
The historical data trend for Axonics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Axonics's Equity-to-Asset
For the Medical Devices subindustry, Axonics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axonics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Axonics's Equity-to-Asset falls into.
Axonics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Axonics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axonics (NAS:AXNX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Axonics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Axonics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AXNX has been successfully added to your 